Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate
Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate Fast Track designation granted by US FDA Feasibility study initiated of a vaccine candidate to address emerging variants Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicago's plant-derived COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant, as part of the ongoing Phase 2/3 study. Medicago received approval from Canadian and US regulatory authorities to proceed with enrollment of hea...